AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,711 AI briefs of material SEC Form 8-K filings by 4,788 companies: 2,325 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,711every one kept
Companies4,788with at least one brief
Recent filings2,325filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
InfuSystem furnished an investor presentation dated November 9, 2026, under Regulation FD. It shows higher profit for the third quarter and nine months of 2026 and gives estimates for 2026 proforma revenue growth of 6%-8% and a low-to-mid 20% margin. For shareholders, the figures show continued profit growth, though the estimates are company projections and not guaranteed results.
- GAAP net income was $3.2 million for the quarter ended September 30, 2026, versus $2.3 million a year earlier.
- Nine-month GAAP net income was $7.4 million in 2026, versus $4.6 million in 2025; nine-month adjusted EBITDA was $24.3 million versus $22.7 million.
- Estimates as of September 30, 2026 call for 2026 proforma revenue growth of 6%-8%.
- Trailing twelve-month net revenue was $144.4 million and liquidity was $64.1 million as of September 30, 2026; net leverage ratio was 0.32x.
Read the filing on SEC.gov ↗
Summit Midstream reported third quarter 2026 net income of $15.9 million, compared with $5.0 million a year earlier, and raised its full-year 2026 Adjusted EBITDA guidance to $250 million to $260 million from $235 million to $255 million. Common stock dividends remain suspended, and the company's total net leverage ratio was approximately 3.9x as of September 30, 2026.
- Q3 2026 net income $15.9 million vs. $5.0 million in Q3 2025; diluted EPS $0.58 vs. a loss of $0.13
- Total revenues $183.0 million vs. $146.9 million a year earlier; Adjusted EBITDA $70.7 million vs. $65.5 million
- 2026 Adjusted EBITDA guidance raised to $250 million to $260 million from $235 million to $255 million
- Common stock dividends remain suspended; Series A Preferred dividend payable to holders of record on December 1, 2026
Read the filing on SEC.gov ↗
Armstrong World Industries said in an investor presentation for the Baird Global Industrial Conference on November 10 and 11, 2026, that it now expects higher full-year 2026 net sales but lower top-end adjusted EBITDA, adjusted diluted EPS and adjusted free cash flow than its October 27, 2026 guidance. The company attributed the change to stronger net sales growth and accelerating inflationary pressures, so shareholders face a mix of higher revenue and narrower profit expectations.
- Net sales guidance raised to $1,788 million to $1,803 million from $1,770 million to $1,800 million
- Adjusted EBITDA guidance lowered to $602 million to $612 million from $605 million to $620 million
- Adjusted diluted EPS guidance set at $8.30 to $8.40, down from $8.30 to $8.50 at the top end
- Adjusted free cash flow guidance set at $380 million to $390 million, down from $380 million to $395 million
Read the filing on SEC.gov ↗
Harrow reported record third-quarter 2026 revenue of $99.3 million, up 39% year over year, and GAAP net income of $9.8 million, which included a $5.0 million litigation settlement gain. The company reaffirmed its full-year revenue guidance of $350 million to $365 million but lowered its Adjusted EBITDA guidance from $80 million to $100 million to more than $40 million, citing a first-half revenue shortfall, lower gross margins and higher spending.
- Q3 2026 revenue of $99.3 million, up 39% year over year; branded revenue of $83.5 million.
- GAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, versus a net loss of $17.3 million in Q2 2026.
- Full-year 2026 Adjusted EBITDA guidance cut from $80 million to $100 million to more than $40 million; revenue guidance of $350 million to $365 million reaffirmed.
- Cash and cash equivalents were $75.3 million as of September 30, 2026.
Read the filing on SEC.gov ↗
GeneDx reported third quarter 2026 revenue of $123.1 million, up 5% year-over-year, and exome and genome volume growth of 25%. The company reiterated its full-year 2026 revenue guidance of $475 to $490 million, but the guidance table shows lower growth targets for exome and genome volume and revenue than the previous guidance. Adjusted net income fell from $16.1 million a year earlier, and the GAAP net loss widened to $12.3 million.
- Q3 2026 revenue $123.1 million, up 5% year-over-year; exome and genome revenue $110.4 million, up 12%
- Adjusted net income $8.6 million versus $16.1 million in Q3 2025; GAAP net loss $12.3 million versus $7.6 million a year earlier
- Full-year 2026 exome and genome volume growth target listed as at least 28%, versus at least 30% previously; exome and genome revenue growth target at least 17%, versus at least 20% previously
- Q4 2026 guidance: revenue $135 million, exome and genome revenue $121 million, 34,500 tests
Read the filing on SEC.gov ↗
ZipRecruiter reported third quarter 2026 revenue of $124.4 million, up 8% year-over-year and above its $118 million to $124 million guidance range, and net income of $5.1 million compared with a net loss of $9.8 million a year earlier. The company raised its full-year 2026 revenue outlook to $468 million to $472 million, up 4% to 5%, from the flat outlook it gave at the start of the year.
- Q3 2026 revenue was $124.4 million, up 8% year-over-year and 5% quarter-over-quarter; Adjusted EBITDA was $20.8 million, above the $13 million to $19 million guidance.
- Q3 2026 net income was $5.1 million, a 4% net income margin, versus a net loss of $9.8 million in Q3 2025.
- Full-year 2026 revenue outlook is $468 million to $472 million; full-year Adjusted EBITDA outlook is $61 million to $65 million.
- Q4 2026 guidance calls for revenue of $118 million to $122 million and Adjusted EBITDA of $16 million to $20 million.
Read the filing on SEC.gov ↗
RPM presented its MAP 2030 operating improvement program at an Investor Day in Cherry Hill, New Jersey, on November 9, 2026. The company set fiscal 2030 targets of $10 billion in revenue, $2 billion in adjusted EBITDA, a 20% adjusted EBITDA margin and a $30 billion market capitalization, up from fiscal 2026 net sales of $7,863 million and adjusted EBITDA of $1,228 million (15.6% margin).
- Fiscal 2026 net sales were $7,863 million, with adjusted EBITDA of $1,228 million, a 15.6% margin.
- Fiscal 2030 targets include $10 billion in revenue and $2 billion in adjusted EBITDA, a 20% margin.
- The presentation is attached as Exhibit 99.1, and the Investor Day event will be recorded with a replay on the company website.
- The company did not provide a reconciliation of its fiscal 2030 adjusted EBITDA target to GAAP, citing terms outside its control.
Read the filing on SEC.gov ↗
Delcath Systems reported third-quarter 2026 revenue of $35.1 million, up from $20.6 million a year earlier, and net income of $7.0 million, compared with $0.8 million. The company raised its full-year 2026 revenue guidance to $115 million to $117 million, which signals continued growth in HEPZATO KIT sales for shareholders.
- Q3 2026 net income of $7.0 million, or $0.17 diluted per share, versus $0.8 million, or $0.02 per share, in Q3 2025
- Q3 2026 HEPZATO KIT revenue of $32.7 million, up from $19.3 million; non-GAAP adjusted EBITDA of $11.5 million, up from $5.3 million
- 2026 guidance raised to $115 million to $117 million in total revenue, with gross margins of 87% to 89% and positive adjusted EBITDA
- Cash and investments of $104.3 million as of September 30, 2026, with no debt
Read the filing on SEC.gov ↗
Orthofix reported third-quarter 2026 net sales of $207.9 million, up 1.1% from $205.6 million a year earlier, and a net loss of $6.1 million, narrowed from $22.8 million. The company lowered its full-year 2026 net sales guidance to $825 million to $830 million from $845 million to $855 million, and its adjusted EBITDA guidance to $86 million to $88 million from $95 million to $98 million, citing weaker U.S. Spine performance.
- Q3 2026 net sales were $207.9 million, up 1.1% reported and 2.3% pro forma constant currency; Global Limb Reconstruction rose 8.5% and Spinal Implants, Biologics and Enabling Technologies fell 1.1%.
- Q3 net loss was $(6.1) million, or $(0.15) per share, versus $(22.8) million, or $(0.57) per share, a year earlier; adjusted EBITDA was $26.0 million versus $24.6 million.
- 2026 net sales guidance was cut to $825 million–$830 million; adjusted EBITDA guidance was cut to $86 million–$88 million.
- Cash, cash equivalents and restricted cash were $86.9 million at September 30, 2026, down from $104.4 million at June 30, 2026.
Read the filing on SEC.gov ↗
Motorcar Parts of America reported fiscal second-quarter net sales of $169.2 million, down from $221.5 million a year earlier, and operating income of $10.0 million, down from $16.4 million. The company cut its fiscal 2027 net sales guidance to $715 million-$740 million from $780 million-$800 million, citing delayed customer orders, which lowers the outlook for shareholders.
- Q2 net sales were $169.2 million versus $221.5 million a year earlier; the company attributed the $37.5 million decline mainly to delayed customer orders and lower tariff pass-throughs.
- Q2 operating income was $10.0 million versus $16.4 million; the quarter included $11.1 million of IEEPA tariff refunds.
- Six-month net loss was $12.1 million, or $0.64 per share, compared with net income of $893,000 a year earlier.
- Fiscal 2027 net sales guidance was revised to $715 million-$740 million from $780 million-$800 million; operating income is estimated at $37 million-$44 million.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.